CAM
SAGE

Connacht Asset Management’s Sage Therapeutics SAGE Stock Holding History

Connacht Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17,637
Closed -$1.53M – 152
2020
Q4 		$1.53M Buy
+17,637
New +$1.3M 0.72% 50

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Connacht Asset Management's SAGE Position: Q1 2021 in Review

Connacht Asset Management sold out of Sage Therapeutics (SAGE) in Q1 2021, closing a stake of 17,637 shares — an estimated $1.53M sold.

Connacht Asset Management first reported a position in SAGE in Q4 2020 and held it in 1 quarter. The position peaked at $1.53M in Q4 2020. 262 funds tracked by Wall St. Rank hold SAGE as of Q1 2021.

  • Connacht Asset Management reported no remaining Sage Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Connacht Asset Management sold 17,637 Sage Therapeutics shares in Q1 2021, an estimated $1.53M.
  • Connacht Asset Management first reported a position in Sage Therapeutics in Q4 2020 and held it in 1 quarter.
  • Connacht Asset Management's Sage Therapeutics position peaked at $1.53M in Q4 2020.
  • 262 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2021.

Based on Connacht Asset Management's 13F filing for Q1 2021, filed 17 May 2021.